Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: A case series

Neuroendocrinology

Volumn 97, Issue 4, 2013, Pages 318-321

  Saranga Perry, Vita ^a   Morse, Brian ^a   Centeno, Barbara ^a   Kvols, Larry ^a   Strosberg, Jonathan ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Carcinoid; Neuroendocrine tumor; Thymus; Treatment

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CORTICOTROPIN; ETOPOSIDE; OCTREOTIDE; PACLITAXEL; PASIREOTIDE; TEMOZOLOMIDE;

ADRENALECTOMY; ADULT; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CASE REPORT; CASE STUDY; CERVICAL LYMPH NODE; CERVICAL LYMPHADENOPATHY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; CYTOREDUCTIVE SURGERY; DYSPNEA; FACE EDEMA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; LYMPH NODE BIOPSY; MALE; MEDIASTINUM LYMPH NODE; MEDIASTINUM MASS; MEDIASTINUM TUMOR; MEDICAL RECORD REVIEW; MIDDLE AGED; MITOSIS RATE; MULTIPLE CYCLE TREATMENT; MULTIPLE ENDOCRINE NEOPLASIA; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SMALL CELL CARCINOMA; SYSTEMIC THERAPY; THORAX PAIN; THYMECTOMY; THYMOMA; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 84879174707     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000345938     Document Type: Article

References (18)

1. Rosai J, Higa E: Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor: clinicopathologic study of cases. Cancer 1972; 29: 1061-1074.
2. Gaur P, Leary C, Yao JC: Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg 2010; 251: 1117-1121.
3. Teh BT, McArdle J, Chan SP, et al: Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine (Baltimore) 1997; 76: 21-29.
4. Gibril F, Chen YJ, Schrump DS, et al: Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003; 88: 1066-1081.
5. Tiffet O, Nicholson AG, Ladas G, Sheppard MN, Goldstraw P: A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus. Chest 2003; 124: 141-146.
6. Moran CA, Suster S: Neuroendocrine carcinomas (carcinoid tumor) of the thymus: a clinicopathologic analysis of 80 cases. Am J Clin Pathol 2000; 114: 100-110.
7. Chaer R, Massad MG, Evans A, Snow NJ, Geha AS: Primary neuroendocrine tumors of the thymus. Ann Thorac Surg 2002; 74: 1733-1740.
8. Wick MR, Rosai J: Neuroendocrine neoplasms of the thymus. Pathol Res Pract 1988; 183: 188-199.
9. de Montpreville VT, Macchiarini P, Dulmet E: Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases. J Thorac Cardiovasc Surg 1996; 111: 134-141.
10. Ekeblad S, Sundin A, Janson ET, et al: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13: 2986-2991.
11. Takahashi T, Hatao K, Yamashita Y, Tanizawa Y: Ectopic ACTH syndrome due to thymic atypical carcinoid treated with combination chemotherapy of cisplatin and etoposide. Intern Med 2003; 42: 1197-1201.
12. Dham A, Truskinovsky AM, Dudek AZ: Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report. J Thorac Oncol 2008; 3: 94-97.
13. Hamada S, Masago K, Mio T, Hirota S, Mishima M: Good clinical response to imatinib mesylate in atypical thymic carcinoid With KIT overexpression. J Clin Oncol 2011; 29:e9-e10.
14. Strosberg JR, Fine RL, Choi J, et al: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.
15. Fine R, Fogelman D, Schreibman S: Effective treatment of neuroendocrine tumors with capecitabine and temozolomide. ASCO Annual Meeting Proceedings. J Clin Oncol, 2005; 23: 4216.
16. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K: Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011; 117: 4617-4622.
17. Rinke A, Muller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
18. Pavel ME, Hainsworth JD, Baudin E, et al: Everolimus plus octreotide long-Acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005-2012.